BrainCool

In the month of June, the US administration and the Centers for Medicare & Medicaid Services (CMS) defined a new approach to establishing "fast track" insurance reimbursement for breakthrough medical products.

The referral period for the new Medicare reimbursement proposal has now expired.
On August 25, Medicare published an editorial (doi:10.1001/jamahealthforum.2023.2780) in the JAMA Health Forum indicating strong support for establishing a fast track regarding reimbursement for FDA breakthrough devices benefiting the Medicare patient population.

CEO Martin Waleij comments:

-“BrainCool has two breakthrough devices in oncology and stroke, which would benefit from the proposal, however no decision has yet been made public.”